An interventional study of multistage shared decision-making program in Diabetes Mellitus, Type 2, sponsored by Maastricht University Medical Center. Enrolling by invitation at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-13.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center — 2 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Maastricht University Medical Center.
Among the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center, this one is the 13th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2024, is one of 34 with no phase, and was the 38th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 40–75 · Healthy volunteers
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 31 across the 36 interventional studies, 72 across the 4 observational. Of the 33 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923644Maastricht University Medical CenterTargeted Precision Nutrition Strategy To Prevent Chronic Metabolic Diseases | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Type 2 diabetes mellitus is a highly prevalent disease, affecting over a million Dutch citizens, leading to severe micro- and macrovascular complications, reduced quality of life, and high healthcare costs. Clinical guidelines recommend a person-centered approach to improve (health)outcomes. However, with rapidly increasing treatment options, both in terms of medication and lifestyle interventions, shared decision making (SDM) is challenging in practice. Therefore, researchers have developed a multistage SDM program consisting of an online patient decision aid for type 2 diabetes mellitus, training for healthcare professionals in SDM, and a preparatory consult to provide patients with the knowledge and confidence to participate in SDM. Strong evidence of (cost)-effectiveness is a key requirement to achieve broad implementation of this program. This pilot study represents an important initial step towards high-quality economic evaluation research, with a focus on the diversity of the study population, burden on participating healthcare practices, and feasibility of outcome measurement.
Rationale: Previous randomized controlled trials researching the effects of shared decision-making (SDM) support through patient decision aids (PDAs) for type 2 diabetes mellitus (T2DM) experienced several challenges related to study procedures, resources, and study management. These challenges include difficulties in recruiting participants, understandability of questionnaires, timely recruitment, and inadvertent recruitment bias. Small-scale piloting is crucial to address uncertainties around the feasibility of trial methods and to refine the study procedures of a large-scale economic evaluation. This protocol outlines a pilot study aimed at evaluating the feasibility of a future trial-based economic evaluation of a multistage SDM program, including a PDA for T2DM in the Netherlands. By conducting a pilot study, the researchers aim to improve the quality of the intended trial-based economic evaluation.
Objectives: Researchers will conduct a pilot study focused on the following questions to prepare for an intended economic evaluation of our multistage SDM program for T2DM: 1) How to recruit and retain a representative sample of patients with T2DM in terms of sociodemographic and clinical background?; 2) How to support primary care practices in managing the challenges associated with study participation?; 3) How to feasibly measure relevant outcomes of SDM for T2DM using valid and reliable measurement instruments?
Study design: The multistage SDM program will be piloted in a cluster-randomized controlled trial using a mixed-methods approach. Four primary care practices will be included, of which two will be randomly assigned to the intervention group and two to the control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention entails a multistage shared decision-making (SDM) program for type 2 diabetes mellitus (T2DM) that combines (1) an online PDA with (2) a preparatory consult for patients, and (3) interprofessional training in the PDA and SDM for healthcare professionals.
Behavioral: multistage shared decision-making program
Patients and healthcare professionals in the control practices will provide and receive usual care according to the national guidelines for T2DM of the Dutch College of General Practitioners (NHG). Participants in the control practices will not have access to the multistage SDM program.
The multistage shared decision-making program consists of 1) an online patient decision aid; 2) preparatory consult to provide patients with the knowledge and confidence to participate in shared decision-making; and 3) training to improve healthcare professionals' skills for shared decision-making.
Sample recruitment
Recruitment rates: how many patients were recruited on average for one month at one location. Time required to recruit to the target Sociodemographic and clinical characteristics
Time frame: 9 months
Sample retention
Retention rates: percentage of participants who completed the study
Time frame: 9 months
Consent rates
Consent rates: number of patients enrolled divided by number of eligible patients
Time frame: 9 months
Recruit to target
Time required to recruit to target sample size
Time frame: 9 months
Age (years)
Age of participating patients in years. Patients are asked to complete a questionnaire at baseline that includes a question regarding their age.
Time frame: Measured at baseline
Sex (self-reported questionnaire)
Sex of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their sex.
Time frame: Measured at baseline
Country of birth (self-reported questionnaire)
Country of birth of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their country of birth.
Time frame: Measured at baseline
Educational level (self-reported questionnaire)
Educational level of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their highest received diploma.
Time frame: Measured at baseline
Financial (self-reported questionnaire)
Make ends meet financially of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their financial situation (i.e. whether they have (not) difficulties in making ends meet financially)
Time frame: Measured at baseline
Work situation (self-reported questionnaire)
Work situation of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their work situation.
Time frame: Measured at baseline
Duration of type 2 diabetes (self-reported questionnaire)
Duration of diabetes of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding how many years they have type 2 diabetes.
Time frame: Measured at baseline
Weight (kg) (self-reported questionnaire)
Weight of participating patients in kg. Patients are asked to complete a questionnaire at baseline that includes a question regarding what their weight in kg is. This measure is used, in combination with height, to calculate their BMI.
Time frame: Measured at baseline
Height (cm) (self-reported questionnaire)
Height of participating patients in kg. Patients are asked to complete a questionnaire at baseline that includes a question regarding what their height in cm is. This measure is used, in combination with weight, to calculate their BMI.
Time frame: Measured at baseline
Medication use (self-reported questionnaire)
Medication use of participating patients in kg. Patients are asked to complete a questionnaire at baseline that includes a question regarding whether they use medication, and if so, whether they take oral medication or inject insulin.
Time frame: Measured at baseline
Medication adherence measured with the Medication Adherence Report Scale (MARS)
Medication adherence measured with the Medication Adherence Report Scale (MARS) test. This test contains six statements regarding medication adherence and patients are asked to indicate whether the statements applies to them on a five point Likert Scale. Patients are asked to complete this test at baseline, 3 months and 9 months follow-up.
Time frame: Baseline, 3-months and 9-months follow-up
Health literacy (self-reported questionnaire)
Health literacy of participating patients measured with the shortened version of the European Health Literacy Survey questionnaire (HLS-EU) Dutch questionnaire (6 questions)
Time frame: Measured at baseline
Study management measured by conducting focus groups with participating healthcare professionals
Assessment of primary care practices' study management challenges (i.e. time constraints and capacity issues). This will be assessed by conducting focus groups with healthcare professionals from the participating general practices.
Time frame: Focus groups will be held at the end of patient inclusion period, 9-months
Patient decisional conflict measured with the decisional conflict scale (DCS)
Decisional conflict measured with the 16-item decisional conflict scale (DCS). Patients will be asked to reflect on the treatment decision they made with their healthcare professional and respond to 16 statements in the DCS using a five-point Likert scale (ranging from completely agree to completely disagree). Besides a total score, the DCS includes five dimensions (i.e. information, support, clarification or values, certainty, and decision quality) with higher scores on a five-point scale indicating more decisional conflict. Patients are asked to complete this questionnaire at baseline, 3 months and 9 months follow-up.
Time frame: Throughout implementation period, 9-months
Patient-rated level of shared decision-making measured with the 3-item CollaboRATE survey
Patient-rated level of shared decision-making is measured by the 3-item CollaboRATE survey. The CollaboRATE survey assesses patients' perception of being informed and engaged in the decision-making steps on a scale of zero (no effort was made) to nine (every effort was made). Patients are asked to complete this questionnaire at baseline, 3 months and 9 months follow-up.
Time frame: Throughout implementation period, 9-months
Patient-rated level of shared decision-making measured with the SDM-Q-9 questionnaire
Patient-rated level of shared decision-making is measured by the SDM-Q-9 questionnaire. The SDM-Q-9 questionnaire measures the extent of shared decision-making durin a consultation between the patient and healthcare professional. This questionnaire consists of nine statements each describing a different step of the shared decision-making process. All items are scored on a six-point Likert scale from zero (completely disagree) to five (completely agree).
Time frame: Throughout implementation period, 9-months
Healthcare professional level of shared decision-making measured with the SDM-Q-Doc questionnaire
The SDM Q-Doc questionnaire (SDM-Q-9 adapted to the healthcare professional viewpoint) is used to measure the level of shared decision-making during a consultation from the perspective of a healthcare professional.
Time frame: Throughout implementation period, 9-months
Patient knowledge measured with tailor-made questions
Patient knowledge is measured with nine tailor-made multiple-choice questions assessing patients' understanding of the (risks and benefits of) glucose-lowering treatments.
Time frame: Measured at baseline
Glycemic control obtained from general practitioner data
Glycemic control of participating patients will be obtained by obtaining HbA1c data from the general practitioner
Time frame: Baseline, 3-months and 9-months follow-up
Health-related quality of life measured with the EuroQol (EQ) 5 Dimension (5D) - 5 Level (5L) questionnaire
Health-related quality of life of participating patients will be measured with the Dutch EuroQol (EQ) 5 Dimension (5D) - 5 Level (5L) This measure facilitates utility calculations and includes the EQ-5D dimension and the EQ visual analog scale (EQ VAS). EQ-5D comprises five dimensions: mobility, self-care, pain, usual activities and anxiety. Each dimension is scored on a five-point Likert score (from no problems to extreme problems). The EQ VAS is used to assess the patient's self-reported health on a visual analog scale.
Time frame: Baseline, 3-months and 9-months follow-up
Medical consumption measured with the iMCQ
Medical consumption will be measured with an adapted version of the institute for Medical technology Assessment (iMTA) Medical Consumption Questionnaire (iMCQ).
Time frame: Baseline, 3-months and 9-months follow-up
Productivity costs measured with the iPCQ
Productivity costs will be measured with an adapted version of the institute for Medical technology Assessment (iMTA) Productivity Costs Questionnaire (iPCQ).
Time frame: Baseline, 3-months and 9-months follow-up
Understandability of measurement tools
Sem-structured interviews with patients will be held to gain insight into the understandability of the measurement tools.
Time frame: Throughout the 9-month implementation period
Plan to share: Yes — The study protocol will be made publicly available as a research article in a scientific journal. The protocol is under review.
Supporting information: Study protocol
Time frame: The study protocol will be made publicly available as a research article in a scientific journal. The protocol is under review (April 2024).
Access criteria: There will be no access criteria for the protocol (open access publication)
Started Feb 2024 (actual). Primary completion is estimated for Nov 2024, 9 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 9 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →